Nutriband Advances AVERSA™ Fentanyl Patch Toward FDA Submission with Scaled Manufacturing
TL;DR
Nutriband's FDA submission for AVERSA Fentanyl patches could unlock major revenue opportunities through its patented abuse-deterrent technology.
Nutriband incorporates aversive agents into fentanyl patches to prevent misuse and has secured global patents with scaled manufacturing through Kindeva.
Nutriband's AVERSA technology makes fentanyl patches safer by preventing accidental exposure and misuse, improving public health outcomes.
Nutriband developed a transdermal patch technology that deters fentanyl abuse through incorporated aversive agents, protected by global patents.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. (NASDAQ: NTRB) has achieved significant manufacturing scale-up for its lead product, AVERSA™ Fentanyl, through collaboration with Kindeva, moving closer to FDA submission and potential global commercialization. The company's innovative technology incorporates aversive agents into fentanyl patches to prevent misuse and accidental exposure, addressing a critical need in the opioid crisis.
The development represents a major milestone for Nutriband, which has built a comprehensive global intellectual property protection strategy securing patents across the United States, Europe, Asia, and Australia. This international patent portfolio strengthens the company's market position and creates barriers to entry for potential competitors. The manufacturing scale-up enables Nutriband to prepare for regulatory submissions while demonstrating production capability to meet potential market demand.
Nutriband's focus on finalizing its development pathway to FDA approval underscores the company's strategic priority to bring AVERSA™ to market. The technology platform can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, representing a versatile solution beyond fentanyl applications. For more information about the company's technology and development progress, visit https://www.Nutriband.com.
The potential FDA approval and subsequent commercialization could unlock major revenue opportunities for Nutriband while addressing a significant public health concern. The abuse-deterrent technology comes at a critical time when opioid misuse remains a pressing healthcare challenge globally. Investors and industry observers can access the latest news and updates relating to NTRB through the company's newsroom at https://ibn.fm/NTRB.
Nutriband's progress with AVERSA™ Fentanyl demonstrates the growing importance of abuse-deterrent formulations in pharmaceutical development. As regulatory agencies increasingly emphasize the need for safer opioid formulations, technologies like AVERSA™ could become standard requirements for transdermal drug delivery systems with abuse potential. The company's advancement through manufacturing scale-up and regulatory preparation positions it to potentially capture early market share in this emerging segment of pharmaceutical innovation.
Curated from InvestorBrandNetwork (IBN)
